Aziz Maksoud, MD
Cardiovascular Disease · Wichita, KSNPI 1003961764
Payments from drug & device makers
Across 913 payments — averaging $928.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$822K
- Medtronic$12K
- E.r. Squibb & Sons, L.L.C.$4K
- Edwards Lifesciences$2K
- Biotronik Inc.$1K
- Abiomed$1K
- plus $4K from 28 others
What the payments were for
- Consulting fees$16,00020%
- Speaking & faculty fees$24,87531%
- Travel & lodging$4,7426%
- Food & beverage$35,15144%
- Education$360%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 606 | $822,213 |
| Medtronic(2 entities) | 52 | $11,775 |
| E.r. Squibb & Sons, L.L.C. | 91 | $4,472 |
| Edwards Lifesciences | 22 | $2,459 |
| Biotronik Inc. | 9 | $1,336 |
| Abiomed | 9 | $1,014 |
| AstraZeneca | 33 | $785 |
| Boston Scientific | 11 | $685 |
| Neovasc Medical Inc | 2 | $377 |
| Amgen | 19 | $257 |
| Novartis | 7 | $192 |
| Coala Life Inc | 1 | $139 |
| Siemens Medical Solutions USA, Inc. | 2 | $135 |
| Shockwave Medical, Inc | 2 | $132 |
| Cvrx, Inc. | 1 | $123 |
| Inari Medical, Inc. | 1 | $120 |
| Kestra Medical Technology Services, Inc. | 6 | $119 |
| Penumbra, Inc. | 1 | $111 |
| Recor Medical Inc | 1 | $111 |
| Bard Peripheral Vascular, Inc. | 1 | $100 |
| Philips North America LLC | 1 | $98 |
| Merck | 6 | $97 |
| Cardiovascular Systems Inc. | 1 | $87 |
| Pfizer | 7 | $85 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 4 | $72 |
| Astellas Pharma US Inc | 4 | $66 |
| Sanofi-aventis U.S. LLC | 3 | $38 |
| Boehringer Ingelheim | 2 | $24 |
| Surmodics, Inc. | 3 | $23 |
| Novo Nordisk | 1 | $21 |
| Heartflow, Inc. | 1 | $18 |
| Alnylam Pharmaceuticals Inc. | 1 | $17 |
| Kowa Pharmaceuticals America, Inc. | 1 | $16 |
| Gilead | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Xience V coronary stent system$15,792
- Dragonfly OCT$10,904
- DRAGONFLY OPSTAR$6,176
- ELIQUIS$3,700
- MitraClip$3,262
- ESPRIT$3,074
- XIENCE V$2,732
- MitraClip System$1,664
- Xience Sierra Coronary Stent System$1,346
- Optis Coronary Imaging System$1,141
- XIENCE SIERRA$876
- Edwards SAPIEN 3 Transcatheter Heart Valve$797
- TrapIT$759
- NHancer Rx$759
- ReCross$759
- Impella$732
- SYMPLICITY G3$676
- OPTIS$560
- Mitra Clip system$551
- COROFLOW$538
How this compares
$847,330 in reported general payments places this provider in the 95th percentile of 175 cardiovascular disease providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 1,174 | $1,273,422 |
| EntrestoSacubitril/Valsartan | 179 | $198,584 |
| Repatha SureclickEvolocumab | 123 | $158,679 |
| XareltoRivaroxaban | 175 | $155,401 |
| BrilintaTicagrelor | 76 | $63,701 |
| Praluent PenAlirocumab | 35 | $34,779 |
| MultaqDronedarone Hcl | 12 | $22,695 |
| Repatha SyringeEvolocumab | 27 | $20,435 |
| Atorvastatin Calcium | 2,167 | $15,414 |
| ClopidogrelClopidogrel Bisulfate | 1,321 | $12,886 |
| Digoxin | 378 | $8,373 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 29 | $7,941 |
| Metoprolol Tartrate | 1,394 | $6,067 |
| Rosuvastatin Calcium | 606 | $5,938 |
| Bumetanide | 143 | $5,717 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $85 | $1,273,4221,174 claims |
| NovartisEntresto | $192 | $198,584179 claims |
| AstraZenecaBrilinta | $785 | $63,70176 claims |
| Sanofi-aventis U.S. LLCMultaq | $38 | $22,69512 claims |
| Boehringer IngelheimPradaxa | $24 | $3,85016 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 175 cardiovascular disease providers in Kansas.
Other cardiovascular disease in Wichita
- Bassem ChehabWichita$5.9M
- Wassim ShaheenWichita$1M
- Thomas AshcomWichita$193K
- Joseph GalichiaWichita$177K
- Layne ReusserWichita$91K
- Hossein AmiraniWichita$18K
- Ahmed MohamedWichita$17K
- Daniel AlvarezWichita$16K
- Freidy EidWichita$13K
- Mohamad FarhatWichita$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.